Study and Monitoring of Multiple Endocrine Neoplasia Type 1

Study Overview
=================
Brief Summary
-----------------
Multiple Endocrine Neoplasia Type I (MEN1) is a rare autosomal dominant disorder, predisposing sufferers to the development of endocrine tumors. The three most commont endocrine disorders of MEN1 are the secretory tumours of the parathyroid, pituitary gland and pancreas, in addition to which other tumours may be observed. The diagnosis of MEN1 is essential for 1) appropriate therapeutic management of proven endocrine disorders, 2) screening for other endocrine and non-endocrine tumours, 3) family screening of affected relatives and 4) monitoring of patients who have been diagnosed. Undiagnosed MEN1 is one of the reasons for therapeutic failure in the management of endocrine damage. Detection is therefore of major importance, and any improvement in early diagnosis can improve management. The natural history of the disease in all its clinical forms remains poorly understood, with published studies of selected or small populations. There are still clinical forms that are difficult to link to the syndrome. These clinical forms need to be specified in order to ensure optimal management. Only a large cohort will lead to the identification of the various forms of this condition and clarify its prognosis.

Official Title
-----------------
Study and Monitoring of Multiple Endocrine Neoplasia Type 1

Conditions
-----------------
MEN1

Intervention / Treatment
-----------------
* Other: Questionnaires


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: SYMPTOMATIC PATIENTS person (adult or minor) who has not opposed participation if the patient is a minor, the parents must not oppose their child's participation, at least two of the three main types of lesions (parathyroid, pancreas, pituitary gland) OR a known isolated tumor, main type or not, associated with the gene mutation of the NEM1 locus on chromosome 11q13 OR an isolated tumor, main type or not, in an individual with a confirmed family history of NEM1 ASYMPTOMATIC PATIENTS WITH A MUTATION - Presence of a characteristic mutation of NEM1 Exclusion Criteria: NA
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Questionnaires|Questionnaires about: Socio-professional situation Lifestyle Health NME 1 specific breast cancer survey Imaging|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| risk of occurrence of each type of MEN1 related tumors | risk of occurrence of each type of MEN1 related tumors in patients with confirmed MEN-1 | Through study completion, an average of 10 years | 
| genotype-phenotype correlation : association of specific mutations (genotype) with the clinical manifestations (phenotype) |  | Through study completion, an average of 10 years | 
| overall survival |  | Through study completion, an average of 10 years | 
| specific survival and life expectancy |  | Through study completion, an average of 10 years | 
| age at Men1 diagnosis globally and according to the initial presentation |  | Through study completion, an average of 10 years | 
| treatment description of each type of MEN1 related tumors as well as their impact on survival and on disease control |  | Through study completion, an average of 10 years |